Role of salt inducible kinase 1 in high glucose-induced lipid accumulation in HepG2 cells and metformin intervention

Life Sciences

Volumn 173, Issue , 2017, Pages 107-115

  Zhang, Yue ^a   Takemori, Hiroshi ^b   Wang, Chang ^a   Fu, JiaHui ^a   Xu, MingWang ^a   Xiong, Liang ^a   Li, NingXu ^a   Wen, XiuYing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b GIFU UNIVERSITY   (Japan)

Author keywords

ACC1; FASN; HepG2 cells; High glucose; Lipogenesis; Metformin; SIK1; SREBP 1c

Indexed keywords

ACC1 PROTEIN; FASN PROTEIN; GLUCOSE; MESSENGER RNA; METFORMIN; PROTEIN; PROTEIN SERINE THREONINE KINASE; SALT INDUCIBLE KINASE 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; SIK1 PROTEIN, HUMAN;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FATTY LIVER; GENE OVEREXPRESSION; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; LIPID STORAGE; LIPOGENESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WESTERN BLOTTING; BIOLOGICAL MODEL; BIOSYNTHESIS; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS;

FATTY LIVER; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSE; HEP G2 CELLS; HUMANS; LIPOGENESIS; METFORMIN; MODELS, BIOLOGICAL; PROTEIN-SERINE-THREONINE KINASES;

EID: 85013471720     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2017.02.001     Document Type: Article

References (44)

1. [1] Lois, K., Young, J., Kumar, S., Obesity; epiphenomenon or cause of metabolic syndrome?. Int. J. Clin. Pract. 62:6 (2008), 932–938.
2. [2] Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A.J., Natale, S., Forlani, G., Melchionda, N., Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:8 (2001), 1844–1850.
3. [3] Kopelman, P.G., Obesity as a medical problem. Nature 404:6778 (2000), 635–643.
4. [4] Lv, Q., Zhen, Q., Liu, L., Gao, R., Yang, S., Zhou, H., Goswami, R., Li, Q., AMP-kinase pathway is involved in tumor necrosis factor alpha-induced lipid accumulation in human hepatoma cells. Life Sci. 131 (2015), 23–29.
5. [5] Tamura, S., Shimomura, I., Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J. Clin. Invest. 115:5 (2005), 1139–1142.
6. [6] Lonardo, A., Bellentani, S., Ratziu, V., Loria, P., Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?. Expert Rev. Gastroenterol. Hepatol. 5:2 (2011), 279–289.
7. [7] Assmann, G., Lipid metabolism disorder: detection and treatment. 5: treatment of hyperlipidemia in manifest coronary heart disease, diabetes mellitus and hypertension. National Cholesterol Initiative. Fortschr. Med. 109:17 (1991), 361–363.
8. [8] Conget Donlo, I., Giménez Alvarez, M., New treatments for type 2 diabetes. Much ado for nothing. Med. Clin. (Barc.) 132:6 (2009), 217–218.
9. [9] Weltman, M.D., Farrell, G.C., Liddle, C., Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 111:6 (1996), 1645–1653.
10. [10] Kang, H., Koppula, S., Houttuynia cordata attenuates lipid accumulation via activation of AMP-activated protein kinase signaling pathway in HepG2 cells. Am. J. Chin. Med. 42:3 (2014), 651–664.
11. [11] Zhang, D., Wang, Y., Ji, Z., Wang, Z., Data on differentially expressed microRNAs in the liver between nonalcoholic fatty liver disease and normal Wistar rat using Solexa sequencing. Data Brief 8 (2016), 280–285.
12. [12] Aoi, W., Naito, Y., Hang, L.P., Uchiyama, K., Akagiri, S., Mizushima, K., Yoshikawa, T., Regular exercise prevents high-sucrose diet-induced fatty liver via improvement of hepatic lipid metabolism. Biochem. Biophys. Res. Commun. 413:2 (2011), 330–335.
13. [13] Wang, R., Kong, X., Cui, A., Liu, X., Xiang, R., Yang, Y., Guan, Y., Fang, F., Chang, Y., Sterol-regulatory-element-binding protein 1c mediates the effect of insulin on the expression of Cidea in mouse hepatocytes. Biochem. J. 430:2 (2010), 245–254.
14. [14] Li, X., Li, Y., Yang, W., Xiao, C., Fu, S., Deng, Q., Ding, H., Wang, Z., Liu, G., Li, X., SREBP-1c overexpression induces triglycerides accumulation through increasing lipid synthesis and decreasing lipid oxidation and VLDL assembly in bovine hepatocytes. J. Steroid Biochem. Mol. Biol. 143 (2014), 174–182.
15. [15] Knebel, B., Haas, J., Hartwig, S., Jacob, S., Köllmer, C., Nitzgen, U., Muller Wieland, D., Kotzka, J., Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. PLoS One 7:2 (2012), e31812–e31815.
16. [16] Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M.F., Goodyear, L.J., Moller, D.E., Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108:8 (2001), 1167–1174.
17. [17] Song, Y.M., Lee, Y.-H., Kim, J.-W., Ham, D.-S., Kang, E.-S., Cha, B.S., Lee, H.C., Lee, B.-W., Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway. Autophagy 11:1 (2015), 46–59.
18. [18] Zang, M., Zuccollo, A., Hou, X., Nagata, D., Walsh, K., Herscovitz, H., Brecher, P., Ruderman, N.B., Cohen, R.A., AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem. 279:46 (2004), 47898–47905.
19. [19] Zhu, H., Moriasi, C.M., Zhang, M., Zhao, Y., Zou, M.H., Phosphorylation of serine 399 in LKB1 protein short form by protein kinase C is required for its nucleocytoplasmic transport and consequent AMP-activated protein kinase (AMPK) activation. J. Biol. Chem. 288:23 (2013), 16495–16505.
20. [20] Pil Hwang, Y., Gyun Kim, H., Choi, J.H., Truong Do, M., Tran, T.P., Chun, H.K., Chung, Y.C., Jeong, T.C., Jeong, H.G., 3-Caffeoyl, 4-dihydrocaffeoylquinic acid from Salicornia herbacea attenuates high glucose-induced hepatic lipogenesis in human HepG2 cells through activation of the liver kinase B1 and silent information regulator T1/AMPK-dependent pathway. Mol. Nutr. Food Res. 57:3 (2013), 471–482.
21. [21] Magalotti, D., Marchesini, G., Ramilli, S., Berzigotti, A., Bianchi, G., Zoli, M., Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. Dig. Liver Dis. 36:6 (2004), 406–411.
22. [22] Garinis, G.A., Fruci, B., Mazza, A., De Siena, M., Abenavoli, S., Gulletta, E., Ventura, V., Greco, M., Abenavoli, L., Belfiore, A., Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int. J. Obes. 34:8 (2010), 1255–1264.
23. [23] Bugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N., David, E., Rizzetto, M., Marchesini, G., A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 100:5 (2005), 1082–1090.
24. [24] Corey, K.E., Vuppalanchi, R., Vos, M., Kohli, R., Molleston, J.P., Wilson, L., Unalp-Arida, A., Cummings, O.W., Lavine, J.E., Chalasani, N., Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 60:3 (2015), 360–367.
25. [25] Katoh, Y., Takemori, H., Lin, X.-Z., Tamura, M., Muraoka, M., Satoh, T., Tsuchiya, Y., Min, L., Doi, J., Miyauchi, A., Witters, L.A., Nakamura, H., Okamoto, M., Silencing the constitutive active transcription factor CREB by the LKB1-SIK signaling Cascade. FEBS J. 273:12 (2006), 2730–2748.
26. [26] Hashimoto, Y.K., Satoh, T., Okamoto, M., Takemori, H., Importance of autophosphorylation at Ser186 in the a-loop of salt inducible kinase 1 for its sustained kinase activity. J. Cell. Biochem. 104:5 (2008), 1724–1739.
27. [27] Rebecca, B., Metabolic regulation by salt inducible kinases. Front. Biol. 6:3 (2011), 231–241.
28. [28] Yu, J., Hu, X., Yang, Z., Takemori, H., Li, Y., Zheng, H., Hong, S., Liao, Q., Wen, X., Salt-inducible kinase 1 is involved in high glucose-induced mesangial cell proliferation mediated by the ALK5 signaling pathway. Int. J. Mol. Med. 32:1 (2013), 151–157.
29. [29] Zheng, H., Hong, S., Yu, J., Wen, X., Effect of zhenqing recipe on non-alcoholic fatty liver in type 2 diabetes rats and the expression of SIK1. Zhongguo Zhong Xi Yi Jie He Za Zhi 34 (2014), 846–852.
30. [30] Yoon, Y.-S., Seo, W.-Y., Lee, M.-W., Kim, S.-T., Koo, S.-H., Salt-inducible kinase regulates hepatic lipogenesis by controlling SREBP-1c phosphorylation. J. Biol. Chem. 284:16 (2009), 10446–10452.
31. [31] Lin, X.-Z., Takemori, H., Katoh, Y., Doi, J., Horike, N., Makino, A., Nonaka, Y., Okamoto, M., Salt-inducible kinase is involved in the ACTH/cAMP-dependent protein kinase signaling in Y1 mouse adrenocortical tumor cells. Mol. Endocrinol. 15:8 (2001), 1264–1276.
32. [32] Gan, R.-Y., Li, H.-B., Recent progress on liver kinase B1 (LKB1): expression, regulation, downstream signaling and cancer suppressive function. Int. J. Mol. Sci. 15:9 (2014), 16698–16718.
33. [33] Smith, D.P., Spicer, J., Smith, A., Swift, S., Ashworth, A., The mouse Peutz-Jeghers syndrome Gene Lkb1 encodes a nuclear protein kinase. Hum. Mol. Genet. 8:8 (1999), 1479–1485.
34. [34] Do, M.T., Kim, H.G., Choi, J.H., Khanal, T., Park, B.H., Tran, T.P., Hwang, Y.P., Na, M., Jeong, H.G., Phillyrin attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/AMP-activated protein kinase-dependent signalling. Food Chem. 136:2 (2013), 415–425.
35. [35] Jaitovich, A., Bertorello, A.M., Intracellular sodium sensing: SIK1 network, hormone action and high blood pressure. Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1802:12 (2010), 1140–1149.
36. [36] Stenström, K., Salt-Inducible Kinase 1: a Novel Regulator Within a Cell Sodium-Sensing Network. 2010, Sundbyberg, Sweden.
37. [37] Takemori, H., Katoh, Y., Horike, N., Doi, J., Okamoto, M., ACTH-induced nucleocytoplasmic translocation of salt-inducible kinase. Implication in the protein kinase a-activated Gene transcription in mouse adrenocortical tumor cells. J. Biol. Chem. 277:44 (2002), 42334–42343.
38. [38] You, M., Matsumoto, M., Pacold, C.M., Cho, W.K., Crabb, D.W., The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 127:6 (2004), 1798–1808.
39. [39] Zang, M., Xu, S., Maitland-Toolan, K.A., Zuccollo, A., Hou, X., Jiang, B., Wierzbicki, M., Verbeuren, T.J., Cohen, R.A., Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55:8 (2006), 2180–2191.
40. [40] Hou, X., Xu, S., Maitland-Toolan, K.A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T.J., Cohen, R.A., Zang, M., SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem. 283:29 (2008), 20015–20026.
41. [41] Wei, S., Zhang, M., Yu, Y., Lan, X., Yao, F., Yan, X., Chen, L., Hatch, G.M., Berberine attenuates development of the hepatic gluconeogenesis and lipid metabolism disorder in type 2 diabetic mice and in palmitate-incubated HepG2 cells through suppression of the HNF-4α miR122 pathway. PLoS One, 11(3), 2016, e0152097.
42. [42] Prip-Buus, C., Perdereau, D., Foufelle, F., Maury, J., Ferre, P., Girard, J., Induction of fatty-acid-synthase Gene expression by glucose in primary culture of rat hepatocytes. Dependency upon Glucokinase activity. Eur. J. Biochem. 230:1 (1995), 309–315.
43. [43] Du, J., Chen, Q., Takemori, H., Xu, H., SIK2 can Be activated by deprivation of nutrition and it inhibits expression of lipogenic genes in adipocytes. Obesity 16:3 (2008), 531–538.
44. [44] Bright, N.J., Thornton, C., Carling, D., The regulation and function of mammalian AMPK-related kinases. Acta Physiol. 196:1 (2009), 15–26.